α-galactosidase

α-Galactosidase is an endogenous glycosidase that can break down oligosaccharides and glycolipids containing α-galactoside bonds and can be used in the study of Fabry disease.

Exo-α-Galactosidase, Bacteroides thetaiotaomicron (EC.3.2.1.22), is a glycoside hydrolase enzyme.

Exo-α-Galactosidase Isoenzyme from Bacteroides thetaiotaomicron (EC.3.2.1.22) is a glycoside hydrolase enzyme.

exo-α-1,2-Galactosidase, Bacteroides thetaiotaomicron, is a glycoside hydrolase.

β-galactosidase mRNA (N1-Methylpseudo-UTP) encodes the bacterial lactose Z gene product, β-galactosidase. This enzyme catalyzes the conversion of β-galactosides into monosaccharides and serves as a universal marker for assessing transfection efficiency. The inclusion of N1-Methylpseudo-UTP reduces the immunogenicity of the generated mRNA.

Alpha-Galactosidase A is a lysosomal exoglycosidase that hydrolyzes the terminal α-galactose residues of glycoconjugates.

Migalastat hydrochloride (GR181413A) is an orally available, potent and competitive inhibitor of alpha-galactosidase A. It promotes the transport of alpha-galactosidase A to the lysosome and can be used in the study of Fabry disease.

4-Nitrophenyl α-D-galactopyranoside (PNP-alpha-D-Gal) is an artificial substrate of 4-nitrophenyl (pNP) glycopyranoside used for detecting α-galactosidase activity. The amount of released pNP increases significantly when PNP-alpha-D-Gal is used as a substrate.

D-Ribonolactone is a sugar lactone and an inhibitor of β-galactosidase in Escherichia coli (Ki: 26 mM).

Tryptophan, N-indol-3-ylacetyl- (Indole-3-acetyl-L-tryptophan) is involved in regulatory mechanisms for the control of auxin activity during physiological and pathophysiological responses. It may also be used in the synthesis of β-D-galactosidase and β-D-glucosidase inhibitors.

β-Galactosidase (GAL) is a glycoside hydrolase that hydrolyzes the β-glycosidic bond formed between galactose and its organic part, and naturally catalyzes the hydrolysis of the galactosidic bond in oligosaccharides and disaccharides for the degradation of lactose and the production of low-lactose and lactose-free lactose products that are beneficial to lactose intolerant patients.

α-N-acetylgalactosidase (EC 3.2.1.4) is a highly specific exoglycosidase capable of effectively hydrolyzing α-N-acetylgalactosamine (GalNAc) linked to serine or threonine residues in glycoproteins (Tn antigen). This enzyme demonstrates activity towards terminal GalNAc in α 1-3 linkages and operates optimally within a pH range of 6.0-7.6, without requiring cofactors or specialized buffer systems.

Raffinose (Melitriose) is an indigestible short-chain oligosaccharide, a trisaccharide composed of galactose, glucose and fructose, found in many plants. It can be hydrolyzed by α-galactosidase (α-GAL) to D-galactose and sucrose.

X-alpha-Gal is a substrate for alpha-galactosidase. It is used for differentiating alpha-galactosidase-positive strains of yeast.

DGJ-pFPhT is a ligand of human α-galactosidase A.

Globotriaosycleramides are glycosphingolipids found in mammalian cell membranes that are synthesized from lactosylceramides . They act as receptors for Shiga and Shiga-like toxins in vitro and in vivo. Globotriaosylceramides accumulate in endothelial cells, pericytes, vascular smooth muscle cells, renal epithelial cells, dorsal ganglia neuronal cells, and myocardial cells in patients with Fabry disease, a lysosomal storage disorder characterized by a deficiency in the enzyme α-galactosidase A. Globotriaosylceramides act as natural resistance factors to HIV infection, interacting with HIV gp120 to prevent its interaction with chemokine co-receptors and subsequent fusion of HIV to host cell membranes. This product contains a mixture of hydroxy fatty acid-containing globotriaosylceramides isolated from porcine red blood cells (RBCs).

Globotriaosycleramides are glycosphingolipids found in mammalian cell membranes that are synthesized from lactosylceramides . They act as receptors for Shiga and Shiga-like toxins in vitro and in vivo. Globotriaosylceramides accumulate in endothelial cells, pericytes, vascular smooth muscle cells, renal epithelial cells, dorsal ganglia neuronal cells, and myocardial cells in patients with Fabry disease, a lysosomal storage disorder characterized by a deficiency in the enzyme α-galactosidase A. Globotriaosylceramides act as natural resistance factors to HIV infection, interacting with HIV gp120 to prevent its interaction with chemokine co-receptors and subsequent fusion of HIV to host cell membranes. This product contains a mixture of hydroxy and non-hydroxy fatty acid-containing globotriaosylceramides isolated from porcine red blood cells (RBCs).

4-Methylumbelliferyl-α-D-Galactopyranoside (4MU-α-Gal) (4-MU-α-Gal) is a fluorogenic substrate of α-galactosidase. In addition to its use in characterizing novel α-galactosidases, 4-MU-α-Gal is used in assays to evaluate deficiency in α-galactosidase activity related to Fabry disease.

Lyso-globotriaosylceramide is a form of globotriaosylceramide that is lacking the fatty acyl group. It binds to Shiga toxin 1 (Stx1) in the presence of cholesterol and phosphatidylcholine but does not bind Stx2. It also reduces viability and aggregation of human neutrophils induced by phorbol 12-myristate 13-acetate when used at concentrations of 50 and 1 μM, respectively. Lyso-globotriaosylceramide accumulates in the brain, heart, kidney, liver, lung, and spleen in a mouse model of Fabry disease, a lysosomal storage disorder characterized by a deficiency in the enzyme α-galactosidase A. It also accumulates in the urine, kidney, and plasma of patients with Fabry disease. Lyso-globotriaosylceramide levels decrease in response to administration of the α-galactosidase inhibitor 1-deoxygalactonojirimycin in a transgenic mouse model of Fabry disease. Decreases in plasma and urine concentrations of lyso-globotriaosylceramide have been used as a biomarker for efficacy of enzyme replacement therapy (ERT) and other therapies in the treatment of Fabry disease.

C18 globotriaosylceramide is an endogenous sphingolipid found in mammalian cell membranes that is synthesized from lactosylceramide . It inhibits aggregation of human neutrophils induced by phorbol 12-myristate 13-acetate (PMA; 10008014) when used at a concentration of 1 μM. C18 globotriaosylceramide acts as a receptor for Shiga toxin in B cell-derived Raji cells and THP-1 monocytes. It accumulates in the brain, heart, kidney, liver, lung, and spleen in a mouse model of Fabry disease, a lysosomal storage disorder characterized by a deficiency in the enzyme α-galactosidase A. C18 globotriaosylceramide also accumulates in endothelial cells, pericytes, vascular smooth muscle cells, renal epithelial cells, dorsal ganglia neuronal cells, and myocardial cells in patients with Fabry disease.

Australine is a pyrrolizidine alkaloid originally isolated fromC. australethat has enzyme inhibitory activities.1,2,3It is an inhibitor of glucoamylase (IC50= 5.8 μM) that also inhibits glucosidase I, sucrase, maltase, andA. nigerα-glucosidase (IC50s = 20, 28, 35, and 28 μM, respectively).2,3Australine is selective for these enzymes over glucosidase II, α- and β-mannosidase, and α- and β-galactosidase up to 500 μM, β-glucosidase, with only 5% inhibition at 66 μM, as well as isomaltase and trehalase (IC50= 97 and 160 μM, respectively). Australine (500 μg/ml) inhibits glycoprotein processing of viral glycoproteins in influenza virus-infected MDCK cells and induces the accumulation of glycoproteins.2 1.Molyneux, R.J., Benson, M., Wong, R.Y., et al.Australine, a novel pyrrolizidine alkaloid glucosidase inhibitor from Castanospermum australJ. Nat. Prod.51(6)1198-1206(1988) 2.Tropea, J.E., Molyneux, R.J., Kaushal, G.P., et al.Australine, a pyrrolizidine alkaloid that inhibits amyloglucosidase and glycoprotein processingBiochemistry28(5)2027-2034(1989) 3.Kato, A., Kano, E., Adachi, I., et al.Australine and related alkaloids: easy structural confirmation by 13C NMR spectral data and biological activitiesTetrahedron Asymmetry14(3)325-331(2003)

Stachyose hydrate is a natual product,it highly promotes proliferation of lactic acid bacteria (LAB) by inducing LAB to produce more α-galactosidase to hydrolyze stachyose.

Migalastat (GR181413A free base) is an orally administered competitive inhibitor of α-galactosidase A (α-Gal A) with an IC50 of 0.04 μM against human α-Gal A.

Raffinose (Standard) is a trisaccharide standard composed of galactose, glucose, and fructose. It is hydrolyzed by α-galactosidase and used for quantitative analysis and biochemical studies.